Exam 15: Drugs for Treating Schizophrenia and Mood Disorders

Discuss the behavioural and medical differences between first-generation, second-generation, and third-generation antidepressant drugs.

Prozac carries a high risk for physical dependence.

Psychotic behaviour has been shown to result from __________.

A patient on antipsychotic medication has jerky, tic-like movements of the face and has been observed smacking her lips and flicking her tongue rapidly. It is likely that this patient is suffering from __________.

Deinstitutionalization __________.

Prior to the 1960s, the severely mentally ill had been mostly treated through large-scale institutionalization.

Tricyclic drugs slow down the reuptake of _________ in the synapse.

Tardive dyskinesia __________.

Patients under treatment with fluoxetine (brand name: Prozac) run an increased risk of seizures.

Describe the mechanism behind the therapeutic effects of fluoxetine (brand name: Prozac) and other SSRI medications.

Originally, chlorpromazine was used as a treatment for __________.

Which of the following is a third-generation antidepressant?

If you had 10 typical antipsychotic drugs, the one that was most effective in treating schizophrenia would be the one that __________.

A major drawback to the treatment of depression with Prozac is __________.

Parkinson's-like symptoms include all of the following, EXCEPT __________.

The subtype of dopamine-sensitive receptors that are affected by typical antipsychotic drugs is ______.

Largactil, Haldol, Navane, and Majeptil are all examples of __________.

In order to detect early signs of agranulocytosis, it is necessary to administer __________.

MAO molecules stimulate the release of dopamine, norepinephrine, and serotonin at the synapse where they operate.

Selective serotonin reuptake inhibitor (SSRI) antidepressants bear no chemical similarity to __________.